Ketamine Derivative Oral Formulation for Zero-Order Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral dosage forms of ketamine derivatives do not provide a zero-order release profile in the gastrointestinal tract, leading to variable absorption and potential adverse effects due to high peak plasma concentrations.
Innovation Solution
A pharmaceutical composition comprising a ketamine derivative, a controlled release polymer, and an anionic sulfate/sulfonate surfactant, formulated into a solid oral dosage form that achieves a zero-order release profile, reducing peak plasma concentrations and improving bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oral dosage forms of ketamine derivatives are used, then the drug can be administered orally, but the release profile is variable and peak plasma concentrations are high leading to adverse effects
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by incorporating specific surfactants (anionic sulfate/sulfonate type) and controlled release polymers, which modify the dissolution and release characteristics of the ketamine derivative to achieve a zero-order release profile
Solution Approach 2:
The invention uses a composite formulation system combining ketamine derivative, controlled release polymer, and anionic sulfate/sulfonate surfactant to create a matrix that provides sustained zero-order release, transforming the single-component conventional formulation into a multi-component controlled release system
2Quantity of substance
If conventional oral dosage forms are used, then administration is simple, but bioavailability is variable and absorption is inconsistent
Solution Approach 1:
The anionic sulfate/sulfonate surfactant acts as an intermediary substance that facilitates the dissolution and absorption of the ketamine derivative by modifying the interface between the drug, gastrointestinal fluids, and absorption membranes, thereby improving bioavailability and absorption consistency
3Object-affected harmful factors
If sustained release is achieved through polymer matrix, then peak concentrations are reduced, but formulation complexity increases
Solution Approach 1:
The patent optimizes the formulation parameters by selecting specific ratios of ketamine derivative to controlled release polymer and anionic sulfate/sulfonate surfactant, which simplifies the formulation development while achieving the desired zero-order release profile and reducing peak concentrations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides sustained drug release, enhancing oral bioavailability and reducing adverse effects by maintaining therapeutic levels over a prolonged period, thus improving safety and efficacy for treating neurological and psychiatric disorders.
Implementation Method 1
Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile in two-stage dissolution medium
Implementation Method 2
a controlled release polymer
Implementation Method 3
an anionic sulfate/sulfonate surfactant
Data Source
AI summary
Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.